EpiAxis announces the appointment of three new directors

EpiAxis announces the appointment of three new directors

EpiAxis Therapeutics has appointed Professor Pamela Munster, a highly regarded medical oncologist in the field of metastatic breast cancer and epigenetics; Keir J Loiacono, an oncology focused business development executive and intellectual property specialist; and Dr...

read more

EPIAXIS EXPANDS ITS PHASE 1 METASTATIC BREAST CANCER TRIAL

EpiAxis Therapeutics, a University of Canberra spin out company, has expanded its clinical trial program to include two additional recruitment centres for its Phase 1b metastatic breast cancer program.  Those centres are open for patient recruitment at the Southern...

read more

 

Professor Sudha Rao